EIF2AK3 and neoplasm: In summary, PDI presents a novel target to selectively overcome tumor cell resistance to ER stress and radiotherapy acquired by activation of the PERK pathway in solid as well as leukemic malignancies while sparing the severe side effects received by direct inhibition of PERK.